Thermo Fisher Scientific Human/Mouse/Porcine MYO7A (aa 16-31) Synthetic Peptide

Applications

Tested Dilution

Publications

Control (Ctrl)

Assay-dependent

-

Product Specifications

Class

Synthetic

Type

Peptide

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Concentration

0.5 mg/mL

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Wet ice

Product Specific Information

PEP-045 is a 16 amino acid synthetic peptide whose sequence corresponds to a sequence found in the N-terminal region, residues 16-31, of murine, porcine, and human myosin VIIa. The sequence of this peptide is (amino to carboxy terminus): S16-G-Q-E-F-D-V-P-I-G-A-V-V-K-L-C31

This peptide may be used for neutralization and control experiments with the polyclonal antibody that reacts with this product and myosin VIIa, catalog # PA1-936. Using a solution of peptide of equal volume and concentration to the corresponding antibody will yield a large molar excess of peptide (~70-fold) for competitive inhibition of antibody-protein binding reactions.

Reconstitute with 0.1 mL of distilled water.

Target Information

Myosin VIIa is a member of the myosin superfamily of actin-based motor proteins. Defects in the myosin VIIa gene are responsible for hearing impairment in shaker-1 (sh1) mice and causes Usher syndrome IB in humans. Usher syndrome associates congenital deafness, vestibular dysfunction, and retinitis pigmentosa and is the most common form of combined deafness and blindness. Structural features of myosin VIIa protein include an ATP binding N-terminal motor domain, a central region which possess five light-chain binding (IQ) motifs, and a C-terminal domain with three myosin tail homology (MyTH4) and talin-like homology regions.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.